标题
Novel targeted therapeutics for MEN2
作者
关键词
-
出版物
ENDOCRINE-RELATED CANCER
Volume 25, Issue 2, Pages T53-T68
出版商
Bioscientifica
发表日期
2018-01-19
DOI
10.1530/erc-17-0297
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study
- (2017) Alain Ravaud et al. EUROPEAN JOURNAL OF CANCER
- Identification of a novel 5-amino-3-(5-cyclopropylisoxazol-3-yl)-1-isopropyl-1H-pyrazole-4-carboxamide as a specific RET kinase inhibitor
- (2017) Hojong Yoon et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Demonstration of a potent RET transcriptional inhibitor for the treatment of medullary thyroid carcinoma based on an ellipticine derivative
- (2017) Vishnu Muthuraj Kumarasamy et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry
- (2017) Oliver Gautschi et al. JOURNAL OF CLINICAL ONCOLOGY
- Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling
- (2017) Sarah K. Nelson-Taylor et al. MOLECULAR CANCER THERAPEUTICS
- Anilinoquinazoline inhibitors of the RET kinase domain—Elaboration of the 7-position
- (2016) Allan M. Jordan et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Discovery of 4-chloro-3-(5-(pyridin-3-yl)-1,2,4-oxadiazole-3-yl)benzamides as novel RET kinase inhibitors
- (2016) Mei Han et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Abstract 2641: The development of potent, selective RET inhibitors that target both wild-type RET and prospectively identified resistance mutations to multi-kinase inhibitors
- (2016) Rami Rahal et al. CANCER RESEARCH
- Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations
- (2016) Gang G. Li et al. CLINICAL CANCER RESEARCH
- An orally available tyrosine kinase ALK and RET dual inhibitor bearing the tetracyclic benzo[b]carbazolone core
- (2016) Zilan Song et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- The discovery of 2-substituted phenol quinazolines as potent RET kinase inhibitors with improved KDR selectivity
- (2016) Rebecca Newton et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- RET kinase inhibitors: a review of recent patents (2012–2015)
- (2016) Luca Mologni et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
- (2016) Jin Li et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Activity of Alectinib in Advanced RET -Rearranged Non–Small Cell Lung Cancer
- (2016) Jessica J. Lin et al. Journal of Thoracic Oncology
- Activity and Safety of Sunitinib in Patients with Advanced Radioiodine Refractory Thyroid Carcinoma: A Retrospective Analysis of 57 Patients
- (2016) Vincent Atallah et al. THYROID
- Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts
- (2016) Elena Andreucci et al. Oncotarget
- Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology
- (2015) Brendan Frett et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- High Affinity Pharmacological Profiling of Dual Inhibitors Targeting RET and VEGFR2 in Inhibition of Kinase and Angiogeneis Events in Medullary Thyroid Carcinoma
- (2015) Nageswara Rao Dunna et al. Asian Pacific Journal of Cancer Prevention
- FDA Approval Summary: Lenvatinib for Progressive, Radio-iodine-Refractory Differentiated Thyroid Cancer
- (2015) A. Nair et al. CLINICAL CANCER RESEARCH
- A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer
- (2015) M. Schlumberger et al. CLINICAL CANCER RESEARCH
- Phase 2 clinical trial of sunitinib as adjunctive treatment in patients with advanced differentiated thyroid cancer
- (2015) Athanasios Bikas et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- A Pyrazolo[3,4-d]pyrimidin-4-amine Derivative Containing an Isoxazole Moiety Is a Selective and Potent Inhibitor of RET Gatekeeper Mutants
- (2015) Hojong Yoon et al. JOURNAL OF MEDICINAL CHEMISTRY
- Rapid Response to Sunitinib in a Patient with Lung Adenocarcinoma Harboring KIF5B-RET Fusion Gene
- (2015) Hsu Wu et al. Journal of Thoracic Oncology
- Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases
- (2015) Vivek Subbiah et al. LUNG CANCER
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Design, Synthesis and Inhibitory Activity of Photoswitchable RET Kinase Inhibitors
- (2015) Rubén Ferreira et al. Scientific Reports
- Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase
- (2015) Marialuisa Moccia et al. PLoS One
- What could Nintedanib (BIBF 1120), a triple inhibitor of VEGFR, PDGFR, and FGFR, add to the current treatment options for patients with metastatic colorectal cancer?
- (2014) Jaume Capdevila et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- A Multicenter Phase 2 Trial of Pazopanib in Metastatic and Progressive Medullary Thyroid Carcinoma: MC057H
- (2014) Keith C. Bible et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
- (2014) Marcia S Brose et al. LANCET
- Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study
- (2014) Shirish M Gadgeel et al. LANCET ONCOLOGY
- Alectinib Shows Potent Antitumor Activity against RET-Rearranged Non-Small Cell Lung Cancer
- (2014) T. Kodama et al. MOLECULAR CANCER THERAPEUTICS
- Oncogenic RET Kinase Domain Mutations Perturb the Autophosphorylation Trajectory by Enhancing Substrate Presentation In trans
- (2014) Iván Plaza-Menacho et al. MOLECULAR CELL
- Selective activity over a constitutively active RET-variant of the oral multikinase inhibitor dovitinib: Results of the CNIO-BR002 phase I-trial
- (2014) Miguel Quintela-Fandino et al. Molecular Oncology
- RET Kinase Inhibitors May Treat Cancer and Gastrointestinal Disorders
- (2014) Ahmed F. Abdel-Magid ACS Medicinal Chemistry Letters
- RET Recognition of GDNF-GFRα1 Ligand by a Composite Binding Site Promotes Membrane-Proximal Self-Association
- (2014) Kerry M. Goodman et al. Cell Reports
- E7080 (Lenvatinib), a Multi-Targeted Tyrosine Kinase Inhibitor, Demonstrates Antitumor Activities Against Colorectal Cancer Xenografts
- (2014) Armin Wiegering et al. NEOPLASIA
- A multi-histology trial of fostamatinib in patients with advanced colorectal, non-small cell lung, head and neck, thyroid, and renal cell carcinomas, and pheochromocytomas
- (2013) Sook Ryun Park et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Vandetanib in Children and Adolescents with Multiple Endocrine Neoplasia Type 2B Associated Medullary Thyroid Carcinoma
- (2013) E. Fox et al. CLINICAL CANCER RESEARCH
- Targeting mTOR in RET mutant medullary and differentiated thyroid cancer cells
- (2013) Matti L Gild et al. ENDOCRINE-RELATED CANCER
- RET inhibition: implications in cancer therapy
- (2013) Maria Grazia Borrello et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Ponatinib (AP24534) Is a Novel Potent Inhibitor of Oncogenic RET Mutants Associated With Thyroid Cancer
- (2013) Valentina De Falco et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Multiple Endocrine Neoplasia Type 2 and Familial Medullary Thyroid Carcinoma: An Update
- (2013) Samuel A. Wells et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Synergistic Cooperation Between Sunitinib and Cisplatin Promotes Apoptotic Cell Death in Human Medullary Thyroid Cancer
- (2013) Alessia Lopergolo et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Cabozantinib in Progressive Medullary Thyroid Cancer
- (2013) Rossella Elisei et al. JOURNAL OF CLINICAL ONCOLOGY
- Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase
- (2013) Luca Mologni et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- In Vitro and In Vivo Activity of Cabozantinib (XL184), an Inhibitor of RET, MET, and VEGFR2, in a Model of Medullary Thyroid Cancer
- (2013) Frauke Bentzien et al. THYROID
- Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors
- (2012) Sara Redaelli et al. AMERICAN JOURNAL OF HEMATOLOGY
- Mechanisms of Resistance to Crizotinib in Patients withALKGene Rearranged Non–Small Cell Lung Cancer
- (2012) Robert C. Doebele et al. CLINICAL CANCER RESEARCH
- CEP-32496: A Novel Orally Active BRAFV600E Inhibitor with Selective Cellular and In Vivo Antitumor Activity
- (2012) J. James et al. MOLECULAR CANCER THERAPEUTICS
- Chemical genetic discovery of targets and anti-targets for cancer polypharmacology
- (2012) Arvin C. Dar et al. NATURE
- Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
- (2012) Ravid Straussman et al. NATURE
- Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias
- (2012) Jorge E. Cortes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sunitinib inhibits papillary thyroid carcinoma with RET/PTC rearrangement but not BRAF mutation
- (2011) Woo-Jin Jeong et al. CANCER BIOLOGY & THERAPY
- Synergistic Action of a RAF Inhibitor and a Dual PI3K/mTOR Inhibitor in Thyroid Cancer
- (2011) N. Jin et al. CLINICAL CANCER RESEARCH
- Development of RET Kinase Inhibitors for Targeted Cancer Therapy
- (2011) L. Mologni CURRENT MEDICINAL CHEMISTRY
- Sorafenib and Mek inhibition is synergistic in medullary thyroid carcinoma in vitro
- (2011) Yoon Woo Koh et al. ENDOCRINE-RELATED CANCER
- Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population
- (2011) Merina Ahmed et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Motesanib and advanced NSCLC: experiences and expectations
- (2011) Kanwal Pratap Singh Raghav et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Antitumour activity of oral E7080, a novel inhibitor of multiple tyrosine kinases, in human sarcoma xenografts
- (2011) Skjalg Bruheim et al. INTERNATIONAL JOURNAL OF CANCER
- Focal Adhesion Kinase (FAK) Binds RET Kinase via Its FERM Domain, Priming a Direct and Reciprocal RET-FAK Transactivation Mechanism
- (2011) Iván Plaza-Menacho et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
- (2011) Razelle Kurzrock et al. JOURNAL OF CLINICAL ONCOLOGY
- Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
- (2011) Samuel A. Wells et al. JOURNAL OF CLINICAL ONCOLOGY
- Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
- (2011) F. M. Yakes et al. MOLECULAR CANCER THERAPEUTICS
- Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma
- (2010) Sarah-Jane Dawson et al. ANTI-CANCER DRUGS
- Structural Mechanism of the Pan-BCR-ABL Inhibitor Ponatinib (AP24534): Lessons for Overcoming Kinase Inhibitor Resistance
- (2010) Tianjun Zhou et al. Chemical Biology & Drug Design
- Targeting RET Receptor Tyrosine Kinase Activation in Cancer
- (2010) J. E. Phay et al. CLINICAL CANCER RESEARCH
- Phase II Study of Daily Sunitinib in FDG-PET-Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging Correlation
- (2010) L. L. Carr et al. CLINICAL CANCER RESEARCH
- RET Is a Heat Shock Protein 90 (HSP90) Client Protein and Is Knocked Down upon HSP90 Pharmacological Block
- (2010) Luigi Alfano et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Phase II Clinical Trial of Sorafenib in Metastatic Medullary Thyroid Cancer
- (2010) Elaine T. Lam et al. JOURNAL OF CLINICAL ONCOLOGY
- Vandetanib for the Treatment of Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer
- (2010) Samuel A. Wells et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study
- (2010) Keith C Bible et al. LANCET ONCOLOGY
- Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symptomatic, Advanced or Metastatic Medullary Thyroid Cancer
- (2009) Martin J. Schlumberger et al. JOURNAL OF CLINICAL ONCOLOGY
- Developmental toxicity associated with receptor tyrosine kinase Ret inhibition in reproductive toxicity testing
- (2008) George R. Clemens et al. BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY
- Therapeutic Options Against BCR-ABL1 T315I-Positive Chronic Myelogenous Leukemia
- (2008) A. Quintas-Cardama et al. CLINICAL CANCER RESEARCH
- Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer
- (2008) Steven I. Sherman et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search